

ALLENEX AB (PUBL)

YEAR-END REPORT 2015

For the October-December period

- Net sales for the period were SEK 34.7 million (30.7).
- Operating income (EBIT) for the period was SEK 9.1 million (9.5).
- Operating margin for the period was 26 percent (31).
- Earnings after tax for the period amounted to SEK 5.6 million (7.2).
- Earnings per share, basic and diluted, for the period were SEK 0.05 (0.05).

For the January-December period

- Net sales for the period were SEK 134.5 million (125.2).
- Operating income (EBIT) for the period was SEK 24.2 million (22.9).
- Operating margin for the period was 18 percent (18).
- Earnings after tax for the period amounted to SEK 15.1 million (15.2).
- Earnings per share, basic and diluted, for the period were SEK 0.13 (0.11).
- The Board of Directors proposes that no dividend be distributed for 2015.

Significant events in the fourth quarter:

- CareDx, Inc., listed on Nasdaq Global Market, USA, made a public takeover offer to the shareholders of Allenex AB to acquire all the outstanding shares in the company. The Board of Directors of Allenex unanimously recommended the shareholders of Allenex to accept the public takeover offer.

Significant events after the period-end:

- CareDx, Inc. announced revised terms of its offer to the shareholders of Allenex AB. The Board of Directors' recommendation to the shareholders of Allenex to accept the offer remains.

President and CEO Anders Karlsson's commentary on 2015:

"Strong growth continued for us in the U.S. throughout 2015. Sales were up for all our key products, in particular for sequence-based typing, SBT. During the year, we forged ties with several large and valuable centers in the U.S. in this segment. EBIT for the full year was 18 percent (18), following a strong closing fourth quarter both from a sales and profitability perspective. We look forward with confidence to the launch of our new product QTYPE®, based on real-time PCR methodology. Active sales of QTYPE® are expected in the first half of 2016."

For more information please contact:


Anders Karlsson, CEO, tel. +46 (0)70-918 00 10 or e-mail: anders.karlsson@allenex.se

GROUP OPERATIONS

Allenex is a Life science company that develops, manufactures, markets and sells products on the global market that facilitate safer transplantation of blood stem cells and organs. Allenex is listed on NASDAQ OMX Stockholm, Small Cap, (ticker: ALNX). There are 57 employees in the Allenex group.


SALES

Net sales for the fourth quarter amounted to SEK 34.7 million (30.7), corresponding to an increase of 13 percent compared to the same period last year.



North America continues to increase in importance for the group, accounting for 30 percent of total sales for the year, while the corresponding figure for the full year 2014 was 23 percent. Growth in this region is primarily driven by new customers in the SBT segment, where three new customers were added in the quarter. Positive developments in SSP sales were also noted in the region. Sales in North America were up by 19 percent in local currency (USD) compared to the same period last year.

Sales in Europe were down seven percent in local currency compared to the full year 2014. Sales in France continued to rise, in particular sales of traditional SSP products, where the company's local representative is linked to a national tender process. Germany showed a negative development for the full-year falling by 15 percent compared to 2014 as a whole. The transplantation scandal that came to light in 2012 continued to have a negative impact on organ donations in the country. Between 2011 and 2014 the number of transplants in Germany using organs from deceased donors decreased from 3 917 to 2 989, a reduction of 25 percent. At the same time, a consolidation of operations to larger laboratory groups and the transition to more automated technologies such as SSO and SBT is ongoing in Germany. However, the negative sales development in Germany subsided in the last quarter. Sales in the emerging markets of India and China for the quarter were lower than the same period last year.



Allenex products are distributed by direct sales through a proprietary sales organization in key markets such as the USA, Germany and in the Nordic region. They are also distributed via partnerships with local distributors in other markets. Registration processes are ongoing for the company's products in a number of countries, with work underway to secure strong local sales/distribution partners in these markets. This has intensified in that the competitors One Lambda and Life Technologies, which were acquired by Thermo Fischer Scientific in recent years, have now chosen to consolidate their operations to one distributor in certain markets.

CUSTOMER GROUPS

Allenex customers largely constitute laboratories active in transplantation diagnostics. Today, there are three different technologies on the market for HLA typing (SSP, SSO and SBT), where the most common typing technique globally, in terms of volume, is SSO. However, most laboratories use SSP typing, either as a primary or supplementary technique. The size of the laboratory and its level of automation determines to what extent the respective methods are used. Today, the largest laboratories mainly utilize automated solutions (SBT and SSO) as their primary technology, while smaller laboratories generally prefer SSP typing. Subsequently, the choice of typing technology is a key parameter for customer categorization.

In recent years, two new further-developed technologies have been tested. These are Next Generation Sequencing (NGS), which primarily targets laboratories that conduct register typing, and Real-Time PCR (also called qPCR), which is mainly used for typing deceased donors prior to an organ transplant. To date, these two technologies are used on a limited scale, however usage is expected to increase in the coming years. It is believed that NGS will primarily compete with SSO and SBT, while Real-Time PCR is expected to mainly compete with SSP and SSO.

Allenex is working to meet market demand for automated typing solutions, in part through proprietary product development, and in part through partnerships with other companies. Since mid-2011, Allenex is the exclusive global distributor of the HLA typing product SBT Resolver™, with the related software Assign-SBT™ from the Australian company Conexio Genomics. SBT Resolver™ was introduced by Allenex in the second half of 2011. This contract gives Allenex greater opportunity to partner with larger, automated laboratories. Since these laboratories to

a large extent strive to use the same supplier for all HLA typing products, this contract will also facilitate increased sales opportunities for Allenex SSP products. SBT Resolver™ has been introduced to a large number of potential customers. Following an introductory demonstration, the laboratory usually conducts an independent comparison to the product currently in use. If the comparison favors Allenex, careful product validation is then carried out prior to fully converting to SBT Resolver™.

The validation process tends to be relatively long, usually taking from 6 to 15 months. At the period end, 42 laboratories had converted, partially or fully, to SBT Resolver™ (26 in North American and 20 in Europa/Asia), with around 10 laboratories at the validation stage.

Abbott Laboratories recently sold the rights to its SBT portfolio to the Dutch company GenDx, which took over the production and distribution of these products from January 2016. It is believed that GenDx will thereby be able to strengthen its product portfolio in Europe by taking over current sales from Abbott. This also opens up opportunities for Allenex to convert certain centers to SBT Resolver™. At the same time, Allenex sees great opportunities in this supplier shift to further increase its market share for SBT Resolver™ in the USA, where GenDx's market penetration is low.

MARKET PERFORMANCE

Traditional SSP typing is still a key technology in the vast majority of HLA laboratories worldwide. Even though the technology has been around for 25 years, it still generates stable sales in most markets. The technology adapts easily to today's needs and this flexibility allows Allenex to continue to regard it as an important part of the company's product mix for the foreseeable future. Despite this, there are of course challenges to address, in particular from the more automated technologies such as SSO, SBT and real-time PCR.

Allenex initial strategy has been to introduce SBT Resolver™ to the largest and most automated HLA laboratories in the U.S. and Europe, to then, in a second phase, focus on converting mid-sized laboratories from competing products. A number of the largest laboratories have very high volumes as they conduct tests for national or regional typing registers. Major register typing laboratories conduct HLA typing tests on more than 5 000 individuals per year and are very careful in their evaluation of new suppliers.

In the USA, in particular, there are larger laboratories where SBT typing is used for clinical typing. In total, around 70 of the 200 HLA laboratories use SBT technology clinically, and of these, 26 laboratories (around 37 percent) have so far chosen Allenex as SBT supplier. Of the 70 laboratories that use SBT technology, around 10 - 15 of them type over 1 500 tissue samples each per year, with a few typing even more than that. These are the laboratories that Allenex has initially chosen to target, as they hold high value as reference customers, which is important in this segment. Among these large laboratories, Allenex currently has four customers. In Europe, the trend is that

larger laboratories or consortiums of laboratories are becoming more active. This is the case in Germany in particular, where a few really large laboratories are taking a more extensive hold of the typing market. There, the demand is for automated solutions that can handle larger volumes, and during the year Allenex entered into an agreement with a large new German customer encompassing the delivery of reagents for SBT typing to this laboratory. This laboratory is one of the very largest in HLA typing in Europe, entailing not only an increase in volumes but also a well-reputed reference center for Allenex.

The distribution agreement between Conexio Genomics and Allenex subsidiary Olerup SSP AB runs through April 2018. In addition to the distribution of SBT Resolver™, the agreement with Conexio Genomics includes two new products for Next Generation Sequencing (NGS), reagents and software. Also included is Gamma Type™, a product for typing of the Gamma block, an area that has not previously been possible to analyze using traditional methods. The introduction of Gamma Type™ began during the first six months of 2015 and Allenex plans to successively introduce the NGS portfolio over the next two years. The new products will provide Allenex with further opportunity to reinforce its leading position in the HLA typing market.

There is currently one actor in the real-time PCR segment, Linkage Bioscience. The company launched products for HLA typing on the American market almost five years ago. The company's products are in use today at some thirty laboratories in the USA, primarily for typing deceased donors. The product line is based on melt curve technology.

PRODUCT DEVELOPMENT

Today, Allenex SSP products hold a strong market position in their field of technology. They are updated on an ongoing basis and the strategy is to offer as close to total solutions as possible.

In 2014, active development began at Allenex on a completely new product group for HLA typing based on Real-Time PCR (q-PCR) methodology. The starting point for the development work is SSP technology, which is at the core of the Allenex product range today. The new product QTYPE® will primarily focus on low-resolution typing in conjunction with organ transplantation and typing that either requires ease of administration and expedient results, or where high-resolution typing is not a requirement, such as in a family-investigation prior to stem cell transplantation. Allenex new product is based on hydrolysis probes, commonly referred to as TAQMAN® technology, and differs from the existing products on the market. This technology has a number of significant advantages compared to melt curve technology.

QTYPE® will initially compete with traditional SSP typing, a sector where Allenex has products today, as well as with existing real-time solutions, but also with SSO. In SSP, the company counts on being able to challenge other suppliers and win market share. Great opportunity to win market share is also seen in SSO, where One Lambda/Thermo Fischer Scientific is dominant

today. When transplanting organs from deceased donors it is of great importance to be able to expediently carry out HLA typing to find an appropriate recipient. Real-Time PCR is a more automated method that provides faster results with a lesser proportion of manual work. Typing with QTYPE® will take around one hour compared to the up to three hours it takes to do traditional SSP typing. In this context, SSO typing is relatively slow, taking 5 - 7 hours to conduct. Besides organ transplantation, the method has applications in other types of medical conditions.

QTYPE® was introduced at the end of April at the European HLA congress, EFI, in Geneva. At the end of September QTYPE® was also presented to the American market at the corresponding American HLA congress, ASHI, in Savannah, Georgia. It is currently estimated that the new product will be ready for launch in the first half of 2016.

Continuous product development is also ongoing at Allenex to maintain its position as market leader in SSP technology. Allenex continues to develop its current product line to ensure high performance in SSP typing. The company is also reviewing solutions adapted to laboratories looking for SSP technology with the possibility of increased automation that can be used as a complement to SSO and SBT technologies. In 2012, Allenex introduced Olerup SSP® Add-ons, a complement to the automated technologies (SSO and SBT). In 2014, additional Olerup SSP® products were introduced with the aim of meeting customer needs for improved HLA typing with traditional SSP technology.

SIGNIFICANT EVENTS IN THE GROUP

Significant events in the first quarter

- Allenex acquired all minority holdings in the group from SSP Primers AB for a consideration of SEK 20 million, as well as repayment of a loan of SEK 4 million. 2014 profit generated by Olerup SSP AB and Olerup International AB was transferred to Allenex.

Significant events in the second quarter

- No significant events occurred in the reporting period.

Significant events in the third quarter

- No significant events occurred in the reporting period.

Significant events in the fourth quarter

- CareDx, Inc., listed on Nasdaq Global Market, USA, announced a public takeover offer to the shareholders of Allenex AB to acquire all the outstanding shares in the company. The Board of Directors of Allenex unanimously recommended the shareholders of Allenex to accept the public takeover offer.

Significant events after period-end

- CareDx, Inc. announced revised terms of its recommended offer to the shareholders of Allenex AB.

FINANCIAL POSITION, CASH FLOW AND FINANCING

Consolidated operating income for the full-year 2015 rose to SEK 24.2 million (22.9). The weakened Swedish krona had a positive impact on revenues compared to the previous year as the majority of these are in EUR and USD. At the same time, the weak Swedish currency had a negative impact on raw material and consumable costs as these are also mainly purchased in EUR and USD.

Unrealized currency gains are included in Other expenses, reducing these by SEK 4.6 million (6.3). Unrealized currency gains also boosted financial items by SEK 0.7 million (3.4). Already realized currency gains of SEK 0.8 million (0.2) are posted in Other expenses.

New product development expenses of SEK 12.8 million (2.8), were capitalized during the year, leaving a closing balance of SEK 15.6 million. The capitalization concerns the development of QTYPE® a new product for HLA typing based on Real-Time PCR (qPCR) methodology.

The group's operations are financed by shareholders' equity and loans. Interest-bearing liabilities amounted to SEK 109.0 million (92.2). The consolidated equity/assets ratio was 58 percent (63). Consolidated equity was SEK 209.5 million (220.5) corresponding to SEK 1.74 per share (1.83). Equity decreased by SEK 20.0 million due to the acquisition of all minority holdings in the group, and increased as the accrued interest of SEK 1.0 million was waived. Cash and cash equivalents totaled SEK 4.3 million (7.3).

Cash flow from operating activities during the year was SEK 14.7 million (10.5). The Investing activities post includes investments in capitalized assets of SEK 12.8 million. The Financing activities post includes the acquisition of minority holdings of SEK 20.0 million less a debt to SSP Primers AB of SEK 14.0 million, net SEK 6.0 million. A new loan to FastPartner AB of SEK 2.0 million, as well as a new bank loan of SEK 10.0 million, amortization of a bank loan of SEK 6.0 million, and a net payment to SSP Primers AB of SEK 10.0 million.

According to an agreement with SSP Primers AB during the first quarter, Allenex acquired 9.0 percent of Olerup SSP AB, 1.9 percent of Absorber AB, 25.0 percent of Olerup International AB as well as 50.0 percent of Olerup Inc. USA. Under the terms of the agreement, SSP Primers AB has waived any further claims on Allenex and the other companies in the group, regarding accrued interest, among other things. 2014 profit in Olerup SSP AB and Olerup International AB was transferred to Allenex in full. The remaining debt to SSP Primers AB will be paid in three installments of SEK 4.0 million (February 2016), SEK 5.0 million (February 2017) and SEK 5.0 million (February 2018). A fixed interest rate of 3 percent paid annually in arrears will be charged on the outstanding amount.

In order to cover the investment costs of the development project for real-time PCR and payment for the acquisition of minority shareholdings, an agreement has been reached for a bridge

loan from the company's principal owners for Q1 2016 operations.

RISKS AND UNCERTAINTIES

Allenex has long been a well-established business with well-known products in the field of genomic HLA typing based on SSP technology, with a significant market share. At the same time, the company faces market risk in the form of competition from other producers, the transition to more automated typing processes as well as new technologies, which may make it difficult for the company to maintain market share and margins.

Operational risk is primarily tied to the company's ability to constantly update its product range and to produce continually updated HLA test kits in pace with market demand.

Products sold and distributed on the basis of cooperation agreements with other companies increase the opportunity of strengthening market position and profitability, while they also carry an increased risk in light of the commitments in terms of resource investments and costs resulting from such agreements. The SBT products from the Australian company Conexio Genomics in particular are expected to achieve significant sales. At the same time, this involves significant competition and market risk. The ability to deliver the right quality on time has both a short and long-term significance for the business. For example, the inability of the partner to deliver due to production downtime could have a substantial negative effect on sales. Allenex has committed to minimum purchasing level from Conexio.

In 2014 and 2015 significant development work was conducted on the new product QTYPE® based on real-time PCR methodology. It is expected that the product will successively generate significant sales. There is a risk that this will take longer than previously planned and that the product will not achieve the success expected. This in turn may have a negative impact on the value of intangible and other assets.

The transplantation test XM-ONE® is primarily established as a research product for larger centers. Work is underway to get the product established in broad clinical use. This has proven to take longer than planned and there is a risk that the product may not attain the success anticipated. This in turn could have a negative on the value of the company's intangible and other assets. To date, XM-ONE® is virtually alone in its field and has significant patent protection. However, work is ongoing at the company's competitors to establish similar testing methods. Therefore, there is a risk that the company's competitors may challenge the position that XM-ONE® has on the market.

The Allenex group has a significant exposure to exchange rate fluctuations due to the fact that most of the company's revenues are in EUR and USD, while costs are partly in SEK. This may signify a currency risk for the company. Allenex does not conduct currency hedging activities.

Attracting and maintaining qualified personnel for development, production, marketing, sales, logistics and administration is essential to group performance.

The value of the company is partly dependent on its ability to maintain and protect patents, other intellectual property rights and specific expertise. Patent protection for medical, medtech and biotech products can be uncertain and involve complex legal and technical issues. Patents must usually be sought and maintained in several jurisdictions, and issued patents may be challenged, invalidated and circumvented. For Allenex or its subsidiaries this may mean loss of or shortened patent protection, which in turn may mean that the company cannot prevent competitors from marketing similar products. The uncertainty associated with patents and patent litigation and other patent processes, may have a negative impact on the competitiveness of Allenex and its subsidiaries, which in turn may have a negative effect on their business.

Both clinical trials and the marketing and sales of products pose a significant risk in terms of product liability. When deemed necessary, the company obtains product liability insurance. No assurance can be given that insurance will cover future claims against Allenex or its subsidiaries.

In certain cases the company is dependent on approval through clinical trials or decisions from public authorities. There are no guarantees that the company will achieve satisfactory results in such trials, or that the required regulatory approval will be granted.

The group's customer relations are stable and long-term, with historically low credit losses. Credit evaluations are carried out on new customers. Credit risk is currently assessed as low, but any change in a negative direction could impact the company's results and financial position.

Part of the financing was raised at variable interest rates, therefore rising interest rates could lead to lower returns for the company, which in turn could affect the company's results and financial position. Based on the current circumstances, the group is of the opinion that it has sufficient liquidity to conduct its operations according to current plans. There is a risk that market conditions and sales will develop negatively, which may have a negative effect on liquidity. The group's ability to re-finance maturing loans may also be adversely impacted by group performance and overall conditions in the financial markets. The company's cash and cash equivalents are placed in liquid assets with low credit risk.

No significant changes in risk assessment have been made compared to the annual report 2014, pages 23-24.

FINANCIAL INSTRUMENTS

Allenex financial instruments consist of trade account receivable, cash and cash equivalents, trade accounts payable, accrued supplier expenses and interest-bearing liabilities. Liabilities to credit institutions have variable interest rates. Liabilities to shareholders and SSP Primers AB have fixed interest rates, which essentially correspond to current market rates. Other financial assets and liabilities have short life spans. The fair value of all financial instruments is deemed to approximate the book value. Allenex has not netted any financial assets or liabilities and has not entered into any offset agreements.

TRANSACTIONS WITH RELATED PARTIES

Transactions with related parties are shown in Note 10 of the Allenex 2014 Annual Report. No substantial changes occurred in the content or scope of these transactions for the period.

PARENT COMPANY

Revenues for the year amounted to SEK 2.7 million (2.7). Operating loss for the quarter was SEK 13.8 million (-13.1). The company's long-term intragroup receivables amounted to SEK 159.7 million (96.0). Cash and cash equivalents were SEK 2.1 million (0.1). At the period end the parent company had 4 employees (4).

SHARE AND SHAREHOLDERS

LARGEST OWNERS 2015-12-31	NO. SHARES	OWNERSHIP STAKE %
Midroc Invest AB	43 678 850	36.3
FastPartner AB (publ)	38 886 307	32.3
Xenella Holding AB *)	11 174 755	9.3
Handelsbanken Liv **)	6 842 887	5.7
Avanza Pension	3 434 206	2.9
Nordnet	1 824 408	1.5
Other	14 447 035	12.0
	20 288 448	100.0

*) Xenella Holding AB is jointly owned by Midroc Invest AB and FastPartner AB (publ).

**) Mannersons Fastigheter ABs holding as per April 14, 2015 was transferred to Handelsbanken Liv.

PUBLIC TAKEOVER OFFER

The U.S. diagnostics company CareDx, Inc. made a public takeover offer on December 16, 2015 to the shareholders of Allenex AB to acquire all the outstanding shares in the company. The company's principal owners Midroc Invest AB, FastPartner AB (publ) and Xenella Holding AB, which control around 78 percent of the shares, have committed to accepting the offer. The Board of Directors of Allenex unanimously recommended the shareholders of Allenex to accept the offer.

In February 2016, CareDx, Inc. announced revised terms in its recommended offer to Allenex shareholders. The revised terms were also unanimously recommended by the Allenex Board of Directors.

If the offer is accepted to such an extent that CareDx becomes owner of more than 90 percent of the total number of shares in Allenex, CareDx intends to initiate compulsory acquisition of the remaining number of shares in accordance with the applicable rules in the Swedish Companies Act (2005:551) and to advocate that the shares be delisted from NASDAQ Stockholm.

ACCOUNTING PRINCIPLES

Allenex applies International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. This interim report was prepared in accordance with IAS 34 and the Annual Accounts Act for the group and for the parent company. The accounting principles and methods of calculation applied for the group and the parent company are consistent with those used in the preparation of the most recent Annual Report.

FUTURE REPORTING DATES

The 2015 Annual Report will be published on Allenex website: April 22, 2016

Interim Report January-March: May 19, 2016

Allenex Annual General Meeting: May 19, 2016

The Annual General Meeting will be held in Stockholm on May 19, 2016. Shareholders wishing to have matters addressed at the meeting should submit their proposals in writing to the company at the following address: Allenex AB (publ), Attn: AGM 2016, Box 122 83, 102 27 Stockholm or via email to arsstamma@allenex.se. All proposals must be received by the company by April 10, 2016 at the latest, or in sufficient time in order to guarantee that their proposals, if required, may be included in the AGM notice.

Stockholm, February 25, 2016

Anders Karlsson
Chief executive officer

The information in this interim report is such that Allenex AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This report and earlier financial reports are available at www.allenex.com

This year-end report has not been subject to review by the company's auditors.

This information was released for publication on February 25, 2016 at 14.00 CET

Consolidated statement of comprehensive income summary

	2015	2014	2015	2014
Amounts in SEK thousand	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Net sales	34 749	30 695	134 548	125 216
Change in inventories	2 208	5 801	4 092	5 384
Capitalized work for own account	724	0	2 354	711
Other revenues	716	770	3 481	4 209
	38 397	37 266	144 475	135 520
Raw materials and consumables	-7 548	-7 556	-29 272	-26 169
Other expenses	-8 155	-8 080	-38 323	-38 850
Employee benefit expenses	-12 572	-11 562	-48 582	-45 161
Depreciation/Amortization	-1 049	-613	-4 130	-2 450
<i>Operating results</i>	9 073	9 455	24 168	22 890
Other financial expenses and income	-1 532	311	-5 241	-2 520
<i>Results after financial items</i>	7 541	9 766	18 927	20 370
Taxes	-1 895	-2 615	-3 795	-5 182
<i>Net income for the period</i>	5 646	7 151	15 132	15 188
<i>Other comprehensive results for the period</i>				
<i>Components that will not be reclassified to net results</i>	-	-	-	-
<i>Components that will be reclassified to net results</i>	-	-	-	-
Translation differences for the period	-1 070	-2 820	-7 139	-6 850
<i>Comprehensive income for the period</i>	4 576	4 331	7 993	8 338
Total results for the period attributable to:				
Owners of the parent company	5 646	5 878	15 132	12 918
Non-controlling interests	-	1 273	-	2 270
Total results for the period attributable to:				
Owners of the parent	4 576	4 972	7 993	10 228
Non-controlling interests	-	-641	-	-1 890
Earnings per share, basic and diluted, SEK	0,05	0,05	0,13	0,11
Average number of outstanding shares, basic and diluted	120 288 448	120 288 448	120 288 448	120 288 448
Number of shares at the period end	120 288 448	120 288 448	120 288 448	120 288 448

Consolidated statement of financial position summary

	2015	2014
Amounts in SEK thousand	DEC 31	DEC 31
Assets		
Goodwill	214 962	215 272
Other intangible assets	74 340	64 776
Tangible assets	3 481	3 278
Deferred tax assets	2 935	4 170
<i>Total non-current assets</i>	<i>295 718</i>	<i>287 496</i>
Inventories	41 269	38 106
Current receivables	18 593	17 002
Cash and cash equivalents	4 294	7 323
<i>Total current assets</i>	<i>64 156</i>	<i>62 431</i>
Total assets	359 874	349 927
Equity and liabilities		
Equity	209 503	220 480
Interest-bearing non-current liabilities	87 870	71 324
Deferred tax liabilities	16 394	14 321
Interest-bearing current liabilities	21 113	20 923
Non-interest bearing current liabilities	24 994	22 879
Total equity and liabilities	359 874	349 927

Consolidated statement of changes in equity

	2015	2014
Amounts in SEK thousand	DEC 31	DEC 31
Opening balance	220 480	215 859
Dividends paid to non-controlling interests	-	-3 717
Acquisition of minority holdings in subsidiaries	-18 970	-
Comprehensive results for the period	7 993	8 338
<i>Closing balance</i>	<i>209 503</i>	<i>220 480</i>
Of which attributable to:		
Owners of the parent company	209 503	231 210
Non-controlling interests	-	-10 730

Consolidated statement of cash flow summary

	2015	2014
Amounts in SEK thousand	JAN-DEC	JAN-DEC
Operating income	24 168	22 890
Adjustment for items not included in the cash flow	-503	-3 832
Financial items	-3 181	-3 012
Taxes paid	-1 565	-504
<i>Cash flow from operations before changes in working capital</i>	<i>18 919</i>	<i>15 542</i>
Increase (-)/Decrease(+) in inventories	-3 053	-6 950
Increase (-)/Decrease(+) in operating receivables	-641	1 072
Increase (-)/Decrease(+) in operating liabilities	-528	802
Cash flow from operating activities	14 697	10 466
Cash flow from investing activities	-14 045	-3 235
Cash flow from financing activities	-3 715	-9 717
Cash flow for the period	-3 063	-2 486
Cash and cash equivalents at the start of the period	7 323	10 046
Exchange rate differences in cash and cash equivalents	34	-237
Cash and cash equivalents at the period-end	4 294	7 323

Parent company income statement

	2015	2014
Amounts in SEK thousand	JAN-DEC	JAN-DEC
Revenues	2 749	2 749
Other external costs	-8 186	-7 738
Personnel costs	-8 281	-7 958
Depreciation/amortization	-112	-109
Operating results	-13 830	-13 056
Other financial expenses and income	-2 135	-778
<i>Results after financial items</i>	-15 965	-13 834
Appropriations		
Group contributions received	22 959	38 355
Group contributions paid	-2 762	-17 158
<i>Results before tax</i>	4 232	7 363
Taxes	-	-
Results for the year	4 232	7 363
Parent company statement of comprehensive income		
Results for the period	4 232	7 363
Other comprehensive results for the period	-	-
Comprehensive results for the period	4 232	7 363

Parent company balance sheet

	2015	2014
Amounts in SEK thousand	DEC 31	DEC 31
Assets		
Tangible assets	84	150
Participations in group companies	77 378	57 378
Non-current intra-group receivables	159 656	96 003
Deferred tax assets	1 626	1 626
<i>Total non-current assets</i>	238 744	155 157
Current receivables	11 502	73 944
Cash and bank	2 144	91
<i>Total current assets</i>	13 646	74 034
Total assets	252 390	229 192
Equity and liabilities		
Equity	169 374	165 143
Non-current liabilities	31 870	19 609
Current liabilities	51 146	44 440
Total equity and liabilities	252 390	229 192
Changes in equity, parent company		
Opening balance	165 143	157 780
Results for the period	4 232	7 363
Closing balance	169 374	165 143

Key figures group

	2015	2014
	JAN-DEC	JAN-DEC
Net sales, SEK thousand	134 548	125 216
Operating income, SEK thousand	24 168	22 890
Earnings after tax, SEK thousand	15 132	15 188
Earnings per share, basic and diluted, SEK	0.13	0.11
Equity per share, SEK	1.74	1.83
Equity/assets ratio, %	58	63
Return on equity, %	7	8
Average number of employees	57	55
Number of shares outstanding at the period-end	120 288 448	120 288 448
Average number of shares outstanding	120 288 448	120 288 448
Share price at the period-end, SEK	2.48	1.92
Market cap, SEK thousand	298 315	230 954

Definitions:

Earnings per share	Earnings after tax attributable to the owners of the parent company divided by the average number of outstanding shares.
Equity per share	Equity divided by the number of outstanding shares at the period end.
Equity/assets ratio	Equity at the period-end in relation to total assets.
Return on equity	Results attributable to parent company shareholders divided by equity attributable to the owners of the parent.
Operating margin	Earnings before financial items divided by net sales

For a more detailed glossary see annual report 2014, page 63

Companies in the Allenex group

PRODUCTION AND R&D COMPANIES



Olerup SSP AB is world leading in the development of kits for genomic HLA typing, based on SSP technology. The product is used prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to hematopoietic stem cell transplantation (bone marrow transplantation) and is also used in conjunction with organ transplants (kidney, lung, heart, etc.). Since 2011, Olerup SSP has an exclusive global agreement (excl. Australia, New Zealand and Taiwan) with Conexio Genomics, Perth, Australia. The agreement runs through April 2018. Allenex ownership stake in Olerup SSP AB is 100 percent. For more information visit www.olerup-ssp.com



AbSorber develops products that facilitate successful transplantation. AbSorber's transplantation test XM-ONE®, identifies antibodies that play a key role in rejection reactions. The company's research portfolio also includes a patented ABO column for transplantations between people of different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies. Allenex ownership stake of AbSorber is 100 percent. For more information visit www.absorber.se

SALES & DISTRIBUTION COMPANIES



Olerup GmbH, based in Vienna, is responsible for sales, distribution and logistics in Europe and the rest of the world excluding North, Central and South America as well as the Nordic region. Sales encompass Olerup SSP's HLA typing products and AbSorber's XM-ONE® transplantation test. Furthermore, from mid-year 2011, the company also sells and distributes products from the Australian company Conexio Genomics. Sales are conducted by a proprietary sales team in Germany, Austria, Belgium, the Netherlands and Slovenia. Sales in other markets are handled by distributors. Allenex ownership stake in Olerup GmbH is 100 percent. For more information visit www.olerup.com



Olerup Inc., domiciled in West Chester, PA, USA, is responsible for the sales, distribution and logistics of Olerup SSP and AbSorber products. Furthermore, since mid-2011, the company sells and distributes products from the Australian company Conexio Genomics. The company has its own sales organization in the US, while sales in Canada and Central and South America are handled by distributors. Allenex ownership stake in Olerup Inc. is 100 percent. For more information visit www.olerup.com